Literature DB >> 20980793

Haemophilus influenzae type b conjugate vaccines: considerations for vaccination schedules and implications for developing countries.

Sean P Fitzwater1, James P Watt, Orin S Levine, Mathuram Santosham.   

Abstract

Prior to widespread vaccination, Haemophilus influenzae type b was a leading cause of severe childhood bacterial infection, including meningitis, worldwide. Over the last decade the world has taken great strides towards controlling Hib disease through routine use of conjugate vaccines in developed and developing countries. Currently there is no consensus on the appropriate schedule by which to use Hib vaccine. Vaccination schedules around the world vary greatly, particularly between high and low income countries. Questions remain as to the most effective and efficient schedule of primary doses, the need for a booster dose, and the implications of using combination vaccines. Here, we present a synthesis of data supporting various Hib vaccine schedules, with a focus on the implications for developing countries.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20980793     DOI: 10.4161/hv.6.10.13017

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  6 in total

1.  Impaired haemophilus influenzae type b transplacental antibody transmission and declining antibody avidity through the first year of life represent potential vulnerabilities for HIV-exposed but -uninfected infants.

Authors:  James T Gaensbauer; Jeremy T Rakhola; Carolyne Onyango-Makumbi; Michael Mubiru; Jamie E Westcott; Nancy F Krebs; Edwin J Asturias; Mary Glenn Fowler; Elizabeth McFarland; Edward N Janoff
Journal:  Clin Vaccine Immunol       Date:  2014-10-08

2.  Delay in booster schedule as a control parameter in vaccination dynamics.

Authors:  Zhen Wang; Gergely Röst; Seyed M Moghadas
Journal:  J Math Biol       Date:  2019-09-07       Impact factor: 2.259

Review 3.  Dose-specific efficacy of Haemophilus influenzae type b conjugate vaccines: a systematic review and meta-analysis of controlled clinical trials.

Authors:  U K Griffiths; A Clark; B Gessner; A Miners; C Sanderson; E R Sedyaningsih; K E Mulholland
Journal:  Epidemiol Infect       Date:  2012-05-14       Impact factor: 2.451

4.  A fine-tuned interaction between trimeric autotransporter haemophilus surface fibrils and vitronectin leads to serum resistance and adherence to respiratory epithelial cells.

Authors:  Birendra Singh; Yu-Ching Su; Tamim Al-Jubair; Oindrilla Mukherjee; Teresia Hallström; Matthias Mörgelin; Anna M Blom; Kristian Riesbeck
Journal:  Infect Immun       Date:  2014-03-24       Impact factor: 3.441

5.  Prospective multi-centre sentinel surveillance for Haemophilus influenzae type b & other bacterial meningitis in Indian children.

Authors:  Padmanabhan Ramachandran; Sean Patrick Fitzwater; Satinder Aneja; Valsan Philip Verghese; Vishwajeet Kumar; Krishnamoorthy Nedunchelian; Nitya Wadhwa; Balaji Veeraraghavan; Rashmi Kumar; Mohamed Meeran; Arti Kapil; Sudha Jasmine; Aarti Kumar; Saradha Suresh; Shinjini Bhatnagar; Kurien Thomas; Shally Awasthi; Mathuram Santosham; Aruna Chandran
Journal:  Indian J Med Res       Date:  2013-04       Impact factor: 2.375

6.  Modelling the effects of booster dose vaccination schedules and recommendations for public health immunization programs: the case of Haemophilus influenzae serotype b.

Authors:  Nadia A Charania; Seyed M Moghadas
Journal:  BMC Public Health       Date:  2017-09-13       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.